Peptide therapy claims on TikTok: what the science says

What did @totalhealthwithdrnick actually say?

Dr. Nick compared two growth hormone-releasing hormone (GHRH) analogs, tesamorelin and sermorelin, and ranked them head-to-head. His core argument: sermorelin is the gentler, anti-aging option with a longer half-life, while tesamorelin is "much stronger," has "stronger IGF stimulation," is "more targeted" for burning belly fat, and is "clinically proven to be more effective" for muscle growth. He closed by directing viewers to his Linktree to purchase peptides.

A few quick clarifications before we get into the science: he repeatedly called sermorelin "Simmer Ellen" and tesamorelin "Tessa Morelen," which is worth noting for any viewer who was confused. These are the same compounds he is describing.

The comparison is not entirely without merit, but several specific claims either outpace the evidence or distort it enough to matter for someone making a health decision.

Does the science back this up?

Partially, but the framing is selective. Tesamorelin's strongest evidence base is specifically in HIV-associated lipodystrophy, not general "belly fat" in the broader population. The FDA approved tesamorelin (Egrifta) in 2010 for reducing visceral adipose tissue in HIV-positive adults with lipodystrophy. That is a narrow, well-defined indication.

Falutz et al. (2010, New England Journal of Medicine) showed tesamorelin significantly reduced visceral fat in HIV patients compared to placebo over 26 weeks. That is real, peer-reviewed data. But extrapolating that finding to general metabolic issues or stubborn belly fat in otherwise healthy patients is a significant leap the studies do not support.

On IGF-1 stimulation, tesamorelin does produce a more robust and sustained IGF-1 response than sermorelin in clinical comparisons, largely because tesamorelin is a stabilized GHRH analog with a longer active half-life in vivo. Sermorelin's half-life in circulation is indeed short, roughly 10-20 minutes, consistent with what he said. Tesamorelin's active period is longer due to its trans-3-hexenoic acid modification.

The muscle growth claim is where things get shakier. There is limited head-to-head data directly comparing tesamorelin and sermorelin for lean mass gains in non-HIV populations.

What did they get wrong (or right)?

He got the half-life comparison roughly right. Sermorelin degrades quickly, and tesamorelin has structural modifications that extend its functional activity. That part holds up.

He got the visceral fat data right in spirit but wrong in scope. Calling tesamorelin "more targeted" for belly fat is defensible if you specify the HIV-lipodystrophy context. Presenting it as a general fat-loss tool for people with "belly fat issues" is misleading. The FDA has not approved tesamorelin for general obesity or metabolic syndrome, and off-label use for cosmetic fat loss is a different conversation than what the clinical trials actually tested.

The claim that tesamorelin is "clinically proven to be more effective" for muscle growth is not well-supported. Falutz et al. (2010) did not find significant differences in lean body mass as a primary outcome. A later analysis by Grunfeld et al. (2012, Journal of Acquired Immune Deficiency Syndromes) showed modest lean mass preservation, but head-to-head superiority over sermorelin for muscle growth in healthy adults is not established in the literature.

The cognitive function claim for sermorelin is largely anecdotal in current literature. There is preclinical interest but no robust human trial data linking sermorelin specifically to cognitive improvement.

What should you actually know?

Both peptides stimulate the pituitary to release growth hormone. Neither is a substitute for medically supervised care, and the evidence base for each matters depending on what you are actually trying to treat.

Tesamorelin has the stronger and more specific clinical evidence, but that evidence is in a defined patient population with HIV-related lipodystrophy. Using that data to market it as a general metabolic or body composition tool for a general TikTok audience is a stretch that the clinical literature does not authorize.

Sermorelin has a longer history of use in growth hormone deficiency and is generally considered lower-risk, but "gentler" does not mean it is without side effects or appropriate for unsupervised use. Both compounds stimulate the GH-IGF-1 axis, which has real downstream effects including insulin resistance risk with chronic use.

The video ends with a direct sales pitch linking to a peptide storefront. That context matters. This is not a neutral educational comparison. Anyone considering either compound should have a conversation with a licensed provider who can order baseline labs, assess actual GH and IGF-1 status, and monitor for adverse effects.